RU2011127454A - SPARC, СВЯЗЫВАЮЩИЙСЯ С ScFv - Google Patents

SPARC, СВЯЗЫВАЮЩИЙСЯ С ScFv Download PDF

Info

Publication number
RU2011127454A
RU2011127454A RU2011127454/10A RU2011127454A RU2011127454A RU 2011127454 A RU2011127454 A RU 2011127454A RU 2011127454/10 A RU2011127454/10 A RU 2011127454/10A RU 2011127454 A RU2011127454 A RU 2011127454A RU 2011127454 A RU2011127454 A RU 2011127454A
Authority
RU
Russia
Prior art keywords
agents
composition according
composition
scfv
antibody
Prior art date
Application number
RU2011127454/10A
Other languages
English (en)
Other versions
RU2477728C1 (ru
Inventor
Вуонг ЧИЕУ
Original Assignee
АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи filed Critical АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи
Publication of RU2011127454A publication Critical patent/RU2011127454A/ru
Application granted granted Critical
Publication of RU2477728C1 publication Critical patent/RU2477728C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

1. Композиция, включающая ScFv, который связывается с белком SPARC с KD, составляющей по меньшей мере 7,8·10M.2. Композиция по п.1, где ScFv включает любую из последовательностей SEQ ID NO:113-116.3. Композиция по п.1, где ScFv, связывающийся с белком SPARC, включает последовательность, которая по меньшей мере на 80% идентична любой из CDR в последовательностях SEQ ID NO:113-116.4. Композиция по любому из пп.1-3, где ScFv связан с терапевтическим или диагностическим средством.5. Композиция по п.4, где указанное терапевтическое или диагностическое средство представляет собой терапевтическое средство, выбранное из группы, состоящей из соединений платины, антифолатов, антиметаболитов, антимитотических средств, ДНК-разлагающих агентов, проапоптотических средств, агентов, индуцирующих дифференцировку, антиангиогенных агентов, антибиотиков, ингибиторов тирозинкиназы, ингибиторов киназы, биологически активных агентов, биологических молекул, гормонов, пептидов, антител, фрагментов антител и их комбинаций.6. Композиция по п.4, где указанным терапевтическим средством является фрагмент антитела, содержащий функциональный Fc-домен антитела.7. Композиция по п.6, где указанный функциональый Fc-домен антитела содержит последовательность SEQ ID NO:118.8. Композиция по п.4, где указанное терапевтическое средство выбрано из группы, состоящей из радионуклидов, адриамицина, анзамициновых антибиотиков, аспарагиназы, блеомицина, бусульфана, цисплатина, карбоплатина, кармустина, капецитабина, хлорамбуцила, цитарабина, циклофосфамида, камптотецина, дакарбазина, дактиномицина, даунорубицина, дексразоксана, доцетаксела, доксорубицина, этопозида, эпотилонов, флоксуридина, флудараб�

Claims (15)

1. Композиция, включающая ScFv, который связывается с белком SPARC с KD, составляющей по меньшей мере 7,8·10-5 M.
2. Композиция по п.1, где ScFv включает любую из последовательностей SEQ ID NO:113-116.
3. Композиция по п.1, где ScFv, связывающийся с белком SPARC, включает последовательность, которая по меньшей мере на 80% идентична любой из CDR в последовательностях SEQ ID NO:113-116.
4. Композиция по любому из пп.1-3, где ScFv связан с терапевтическим или диагностическим средством.
5. Композиция по п.4, где указанное терапевтическое или диагностическое средство представляет собой терапевтическое средство, выбранное из группы, состоящей из соединений платины, антифолатов, антиметаболитов, антимитотических средств, ДНК-разлагающих агентов, проапоптотических средств, агентов, индуцирующих дифференцировку, антиангиогенных агентов, антибиотиков, ингибиторов тирозинкиназы, ингибиторов киназы, биологически активных агентов, биологических молекул, гормонов, пептидов, антител, фрагментов антител и их комбинаций.
6. Композиция по п.4, где указанным терапевтическим средством является фрагмент антитела, содержащий функциональный Fc-домен антитела.
7. Композиция по п.6, где указанный функциональый Fc-домен антитела содержит последовательность SEQ ID NO:118.
8. Композиция по п.4, где указанное терапевтическое средство выбрано из группы, состоящей из радионуклидов, адриамицина, анзамициновых антибиотиков, аспарагиназы, блеомицина, бусульфана, цисплатина, карбоплатина, кармустина, капецитабина, хлорамбуцила, цитарабина, циклофосфамида, камптотецина, дакарбазина, дактиномицина, даунорубицина, дексразоксана, доцетаксела, доксорубицина, этопозида, эпотилонов, флоксуридина, флударабина, фторурацила, гемцитабина, гидроксимочевины, идарубицина, ифосфамида, иринотекана, ломустина, мехлоретамина, меркаптопурина, мелфалана, метотрексата, рапамицина (сиролимуса), митомицина, митотана, митоксантрона, нитрозомочевины, паклитаксела, памидроната, пентостатина, пликамицина, прокарбазина, ритуксимаба, стрептозоцина, тенипозида, тиогуанина, тиотепы, таксанов, винбластина, винкристина, винорелбина, таксола, комбретастатинов, дискодермолидов, трансплатинума, 5-фторурацила, соединений, направленных против фактора роста эндотелия сосудов («анти-VEGF антител»), соединений, направленных против рецепторов эпидермального фактора роста («анти-EGFR антител»), генистеина, tTF, TNF, пептида р44, происходящего от Smar1, интерферона, TRAIL, Smac, VHL, прокаспазы, каспазы и IL-2, фрагмента, не являющегося Fc-доменом антитела, и их комбинаций.
9. Композиция по п.4, где указанным терапевтическим или диагностическим средством является диагностическое средство, выбранное из группы, состоящей из радиоактивных веществ, контрастных веществ для МРТ, контрастных веществ для рентгенографии, контрастных веществ для ультразвуковой диагностики и контрастных веществ для ПЭТ.
10. Композиция по любому из пп.1-3, дополнительно включающая фармацевтический носитель.
11. Способ лечения млекопитающего, страдающего заболеванием, включающий введение терапевтически эффективного количества композиции по любому из пп.1-10.
12. Способ по п.11, где заболевание представляет собой аномальную пролиферацию клеток, ремоделирование тканей, гиперплазию, аномальное заживление ран в любой ткани организма и их комбинации.
13. Способ по п.11, где заболевание представляет собой диабетическую или другую ретинопатию, воспаление, фиброз, артрит, рестеноз кровеносных сосудов или искусственных трансплантатов кровеносных сосудов или внутрисосудистых приспособлений и т.п., катаракту и дегенерацию желтого пятна, остеопороз, заболевания костей, атеросклероз и другие заболевания, при которых часто наблюдается кальциноз.
14. Способ по п.11, где указанное заболевание представляет собой рак.
15. Способ по любому из пп.11-14, где указанное млекопитающее представляет собой человека.
RU2011127454/10A 2008-12-05 2009-12-07 SPARC, СВЯЗЫВАЮЩИЙСЯ С ScFv RU2477728C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12022808P 2008-12-05 2008-12-05
US61/120,228 2008-12-05
PCT/US2009/067032 WO2010065969A1 (en) 2008-12-05 2009-12-07 Sparc binding scfcs

Publications (2)

Publication Number Publication Date
RU2011127454A true RU2011127454A (ru) 2013-01-10
RU2477728C1 RU2477728C1 (ru) 2013-03-20

Family

ID=42233653

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2011127456/10A RU2491085C2 (ru) 2008-12-05 2009-12-07 Sparc-связующие пептиды и их применение
RU2011127454/10A RU2477728C1 (ru) 2008-12-05 2009-12-07 SPARC, СВЯЗЫВАЮЩИЙСЯ С ScFv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2011127456/10A RU2491085C2 (ru) 2008-12-05 2009-12-07 Sparc-связующие пептиды и их применение

Country Status (14)

Country Link
US (7) US8445637B2 (ru)
EP (3) EP3059247B1 (ru)
JP (3) JP2012511032A (ru)
KR (3) KR20110100260A (ru)
CN (6) CN104174025B (ru)
AU (2) AU2009322130B2 (ru)
BR (2) BRPI0922790A2 (ru)
CA (4) CA2896413A1 (ru)
ES (1) ES2647351T3 (ru)
MX (2) MX2011005966A (ru)
NZ (6) NZ623264A (ru)
RU (2) RU2491085C2 (ru)
WO (2) WO2010065969A1 (ru)
ZA (1) ZA201104122B (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5484674B2 (ja) 2005-03-04 2014-05-07 シー・アール・バード・インコーポレーテッド アクセスポートおよびその識別方法
US7947022B2 (en) 2005-03-04 2011-05-24 C. R. Bard, Inc. Access port identification systems and methods
US9474888B2 (en) 2005-03-04 2016-10-25 C. R. Bard, Inc. Implantable access port including a sandwiched radiopaque insert
US8029482B2 (en) 2005-03-04 2011-10-04 C. R. Bard, Inc. Systems and methods for radiographically identifying an access port
US10307581B2 (en) 2005-04-27 2019-06-04 C. R. Bard, Inc. Reinforced septum for an implantable medical device
EP3884989B1 (en) 2005-04-27 2022-07-13 C. R. Bard, Inc. Vascular access port
US9642986B2 (en) 2006-11-08 2017-05-09 C. R. Bard, Inc. Resource information key for an insertable medical device
US9579496B2 (en) 2007-11-07 2017-02-28 C. R. Bard, Inc. Radiopaque and septum-based indicators for a multi-lumen implantable port
US8932271B2 (en) 2008-11-13 2015-01-13 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
US11890443B2 (en) 2008-11-13 2024-02-06 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
EP3059247B1 (en) * 2008-12-05 2017-09-20 Abraxis BioScience, LLC Sparc binding peptides and uses thereof
EP2485739B1 (en) * 2009-10-09 2014-12-10 Singapore Health Services PTE. Ltd. Methods and compositions for maintenance of a functional wound
US9079004B2 (en) 2009-11-17 2015-07-14 C. R. Bard, Inc. Overmolded access port including anchoring and identification features
SG11201403062YA (en) 2011-12-13 2014-07-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
CN102775502A (zh) * 2012-08-16 2012-11-14 天津禹王生物医药科技有限公司 α干扰素融合蛋白
US20170226216A1 (en) 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
US10898582B2 (en) 2014-12-11 2021-01-26 University Of Utah Research Foundation Bi-functional allosteric protein-drug molecules for targeted therapy
ES2895640T3 (es) 2014-12-12 2022-02-22 2Seventy Bio Inc Receptores de antígenos quiméricos de BCMA
CA2994279A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
AU2017252574B2 (en) 2016-04-22 2024-08-22 Acceleron Pharma Inc. ALK7 binding proteins and uses thereof
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
WO2018053201A1 (en) 2016-09-14 2018-03-22 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
KR20190064600A (ko) 2016-09-23 2019-06-10 듀크 유니버시티 Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
CN110248645B (zh) * 2016-12-29 2022-04-26 韩国科学技术研究院 基于外来体的抗癌剂
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
JP7433222B2 (ja) 2017-10-25 2024-02-19 アクセレロン ファーマ インコーポレーテッド Ａｌｋ７結合タンパク質およびその使用
GB201721308D0 (en) * 2017-12-19 2018-01-31 Nordic Bioscience As SPARC assay
US20210060171A1 (en) * 2018-01-26 2021-03-04 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
KR102362621B1 (ko) * 2020-06-17 2022-02-14 한국타이어앤테크놀로지 주식회사 리그닌 화합물을 포함하는 친환경 타이어용 고무 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
DE3382317D1 (de) 1982-03-15 1991-07-25 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4952394A (en) 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5618528A (en) 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
US6204054B1 (en) * 1995-09-21 2001-03-20 Andaris Limited Transcytosis vehicles and enchancers for drug delivery
EP1012280B1 (en) 1997-06-11 2004-11-10 Borean Pharma A/S Trimerising module
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
WO2000006605A2 (en) 1998-07-28 2000-02-10 Micromet Ag Heterominibodies
EP1181058A2 (de) 1999-05-27 2002-02-27 Max-Delbrück-Centrum Für Molekulare Medizin Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
CA2407352A1 (en) * 2000-04-21 2001-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
US7125960B2 (en) * 2001-05-30 2006-10-24 Chisso Corporation Crosslinked elastin and process for producing the same
JP2004020357A (ja) * 2002-06-17 2004-01-22 Hidetsugu Ikegami 非熱核融合反応発生方法における非熱核融合燃料温度制御方法
ITMI20021527A1 (it) * 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
EP1440981A3 (en) 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
WO2004085621A2 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
JP2007515949A (ja) * 2003-11-13 2007-06-21 ジェネンテック・インコーポレーテッド スクリーニングアッセイ及び腫瘍治療の方法
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
EP1755653B1 (en) * 2004-05-14 2014-12-31 Abraxis BioScience, LLC Treatment methods utilizing albumin-binding proteins as targets
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
EP1813943B1 (en) * 2004-10-19 2009-09-23 Kumamoto University Novel diagnostic kit for malignant melanoma
ES2565543T3 (es) * 2005-01-24 2016-04-05 Board Of Regents, The University Of Texas System Construcciones de fusión a Fc de unión a fosfatidilserina y su uso terapéutico
EP1869077A2 (en) * 2005-02-18 2007-12-26 Abraxis BioScience, Inc. Q3 sparc deletion mutant and uses thereof
CN105418751B (zh) 2006-06-16 2019-03-05 肿瘤疗法·科学股份有限公司 来自sparc的癌排斥抗原肽以及含有该肽的药物
JP2010502221A (ja) * 2006-09-08 2010-01-28 アンブルックス，インコーポレイテッド 脊椎動物細胞による非天然アミノ酸の部位特異的組み込み
WO2008143708A2 (en) 2006-12-07 2008-11-27 Mayo Foundation For Medical Education And Research Methods and materials related to anti-amyloid antibodies
AT504702A1 (de) * 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
CN101678078B (zh) 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 Sparc及其使用方法
EP3059247B1 (en) * 2008-12-05 2017-09-20 Abraxis BioScience, LLC Sparc binding peptides and uses thereof

Also Published As

Publication number Publication date
CA2808320A1 (en) 2010-06-10
EP2376534A1 (en) 2011-10-19
CA2896413A1 (en) 2010-06-10
BRPI0923155A2 (pt) 2018-10-23
US20140341905A1 (en) 2014-11-20
KR20140071501A (ko) 2014-06-11
KR101413480B1 (ko) 2014-07-10
WO2010065954A3 (en) 2010-08-05
CN102272159A (zh) 2011-12-07
CN104940928B (zh) 2018-03-30
CA2745923A1 (en) 2010-06-10
US20120014954A1 (en) 2012-01-19
RU2491085C2 (ru) 2013-08-27
WO2010065954A2 (en) 2010-06-10
AU2009322130B2 (en) 2013-06-13
NZ593173A (en) 2012-12-21
CN106905429A (zh) 2017-06-30
CN104127879A (zh) 2014-11-05
ES2647351T3 (es) 2017-12-21
CN104127879B (zh) 2017-05-10
BRPI0922790A2 (pt) 2018-11-06
WO2010065969A1 (en) 2010-06-10
CN102272159B (zh) 2015-06-03
EP3059247A1 (en) 2016-08-24
NZ602824A (en) 2014-05-30
JP5580329B2 (ja) 2014-08-27
MX2011005966A (es) 2011-06-30
CN102281890A (zh) 2011-12-14
US8809507B2 (en) 2014-08-19
US20140341904A1 (en) 2014-11-20
KR20110100260A (ko) 2011-09-09
AU2009322130A1 (en) 2011-06-23
NZ623273A (en) 2015-09-25
CN104174025A (zh) 2014-12-03
US8821836B2 (en) 2014-09-02
NZ593281A (en) 2012-12-21
KR101523705B1 (ko) 2015-05-28
US20160304592A1 (en) 2016-10-20
NZ602794A (en) 2014-04-30
MX2011005967A (es) 2011-06-30
CN104940928A (zh) 2015-09-30
US20120039801A1 (en) 2012-02-16
RU2011127456A (ru) 2013-01-10
ZA201104122B (en) 2012-02-29
US9308279B2 (en) 2016-04-12
EP3059247B1 (en) 2017-09-20
US8445637B2 (en) 2013-05-21
US20140370016A1 (en) 2014-12-18
CA2745904C (en) 2014-07-08
EP2376534A4 (en) 2012-05-30
JP2012511030A (ja) 2012-05-17
RU2477728C1 (ru) 2013-03-20
CA2745923C (en) 2018-12-04
JP2012511032A (ja) 2012-05-17
EP2381952B1 (en) 2016-03-09
CN104174025B (zh) 2017-01-11
AU2009322145A1 (en) 2011-06-23
EP2381952A2 (en) 2011-11-02
WO2010065969A8 (en) 2011-05-12
US9314537B2 (en) 2016-04-19
KR20110119631A (ko) 2011-11-02
CA2808320C (en) 2015-09-29
US20130315823A1 (en) 2013-11-28
CN102281890B (zh) 2014-08-20
US10053504B2 (en) 2018-08-21
EP2381952A4 (en) 2012-05-30
NZ623264A (en) 2015-09-25
JP2014221800A (ja) 2014-11-27
US9295733B2 (en) 2016-03-29
CA2745904A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
RU2011127454A (ru) SPARC, СВЯЗЫВАЮЩИЙСЯ С ScFv
Williams Biocompatibility pathways: biomaterials-induced sterile inflammation, mechanotransduction, and principles of biocompatibility control
Doloff et al. Colony stimulating factor-1 receptor is a central component of the foreign body response to biomaterial implants in rodents and non-human primates
Stravinskas et al. Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: in vitro and clinical release studies
Christo et al. Innate immunity and biomaterials at the nexus: friends or foes
Zimmerli et al. Pathogenesis of implant-associated infection: the role of the host
EP2036583A2 (de) Stent mit einer Beschichtung
RU2011127422A (ru) Опосредованное альбумин-связывающим пептидом прицельное воздействие на заболевания
JP2024119854A (ja) β－リン酸三カルシウム結合配列を含むポリペプチドとその使用
EP3413937A1 (en) Compositions and methods for preparation of composite polymer coatings on medical implants, and their use for co-delivery of multiple antimicrobial agents
EP3419679A1 (en) Implantable drug delivery systems
Liu et al. Sustained delivery of a heterodimer bone morphogenetic protein-2/7 via a collagen hydroxyapatite scaffold accelerates and improves critical femoral defect healing
EP2475325B1 (en) Compositions and methods for detecting and treating implant loosening and osteolysis
JP7400145B1 (ja) 複数の電界紡糸繊維からなる綿形状の構造を有する骨再生用材料
Auquit-Auckbur et al. Role of toll-like receptor 4 in the inflammation reaction surrounding silicone prosthesis
Park et al. Bioactivated lubricant-infused surfaces: A dual-action strategy for enhancing osseointegration and preventing implant-associated infections
WO2019099813A1 (en) Multilayered biologic mesh and methods of use thereof
Zhang et al. Vancomycin-encapsulated hydrogel loaded microarc-oxidized 3D-printed porous Ti6Al4V implant for infected bone defects: Reconstruction, anti-infection, and osseointegration
Eid Infected orthopedic implants
CN104507493B (zh) 防止血小板活化的装置和方法
Shah et al. Bioactive sutures: advances in surgical suture functionalization
Simon et al. Permacol interposition graft as an alternative to vein in contaminated wounds using a rabbit model
Fetz Electrospun Biomaterial-Induced Neutrophil Extracellular Traps: Characterization and Regulation for Biomaterial-Guided Tissue Regeneration
Storm Influence of polymer surface modification and specific growth factor stimulation on cellular adhesion at the implant/endothelium interface
Paderi et al. Targeting the Vessel Wall During Vascular Intervention With SB-030 Prevents Platelet Activation and Subsequent Neointimal Hyperplasia

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20181208